title: Second line therapy in malignant pleural mesothelioma: A systematic review.
abstract: After the implementation of standard first line chemotherapy with platinum and antifolates in pleural mesothelioma, patients are confronted with a need for second line treatment at relapse or progression. We conducted a systematic review of the literature for the activity, effectiveness and toxicity of second line treatment. The results are presented according to the class of drugs: chemotherapy and targeted or biological agent.
authors.affiliation: Thoraxoncologie, Nederlands Kanker Instituut, Amsterdam, The Netherlands.
authors.forename: Wieneke A
authors.initials: WA
authors.lastname: Buikhuisen
authors.affiliation: Thoraxoncologie, Universitair Ziekenhuis Antwerpen, Belgium.
authors.forename: Birgitta I
authors.initials: BI
authors.lastname: Hiddinga
authors.affiliation: Thoraxoncologie, Nederlands Kanker Instituut, Amsterdam, The Netherlands.
authors.forename: Paul
authors.initials: P
authors.lastname: Baas
authors.affiliation: Thoraxoncologie, Universitair Ziekenhuis Antwerpen, Belgium. Electronic address: p.baas@nki.nl.
authors.forename: Jan P
authors.initials: JP
authors.lastname: van Meerbeeck
mesh_terms: D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000628:therapy*; D008654:Mesothelioma / Q000235:genetics / Q000628:therapy*; D000086002:Mesothelioma, Malignant; D010997:Pleural Neoplasms / Q000235:genetics / Q000628:therapy*; D019233:Retreatment; D016896:Treatment Outcome
keywords: Biological; Chemotherapy; Mesothelioma; Meta-analysis; Outcome; Second line; Targeted treatment; Treatment